Works Cited

1. Pizzo PA, Clark NM. Alleviating suffering 101: pain relief in the United States. N Engl J Med. 2012;366(3):197-199.

2. Institute for Clinical Systems Improvement. Pain: Assessment, Non-Opioid Treatment Approaches and Opioid Management. Available at Last accessed October 21, 2022.

3. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.

4. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441-451.

5. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci. 2009;32(12):611-618.

6. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73(4):638-652.

7. Widerström-Noga EG, Finnerup NB, Siddall PJ. Biopsychosocial perspective on a mechanisms-based approach to assessment and treatment of pain following spinal cord injury. J Rehabil Res Dev. 2009;46(1):1-12.

8. Buckalew N, Haut MW, Aizenstein H, et al. Differences in brain structure and function in older adults with self-reported disabling and nondisabling chronic low back pain. Pain Med. 2010;11(8):1183-1197.

9. American Society of Anesthesiologists Task Force on Chronic Pain Management. Practice guidelines for chronic pain management. Anesthesiology. 2010;112(4):810-833.

10. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895-926.

11. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1-32.

12. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-491.

13. National Comprehensive Cancer Network. Adult cancer pain. J Natl Compr Canc Netw. 2010;8:1046-1086.

14. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251.

15. Woolf CJ. What is this thing called pain? J Clin Invest. 2010;120:3742-3744.

16. Chen H, Lamer TJ, Rho RH, et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc. 2004;79(12):1533-1545.

17. Whitten CE, Donovan M, Cristobal K. Treating chronic pain: new knowledge, more choices. Perm J. 2005;9:9-19.

18. Charlton JE. Core Curriculum for Professional Education in Pain. 3rd ed. Seattle, WA: IASP Press; 2005.

19. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007;26(4):465-473.

20. Willis WD. The somatosensory system, with emphasis on structures important for pain. Brain Res Rev. 2007;55(2):297-313.

21. Zhuo M. Neuronal mechanism for neuropathic pain. Mol Pain. 2007;3:14.

22. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-S15.

23. Cheng TH. Spinal cord mechanisms of chronic pain and clinical implications. Curr Pain Headache Rep. 2010;14(3):213-220.

24. Stein C, Clark JD, Oh U, et al. Peripheral mechanisms of pain and analgesia. Brain Res Rev. 2009;60:90-113.

25. Henry DE, Chiodo AE, Yang W. Central nervous system reorganization in a variety of chronic pain states: a review. PM R. 2011;3(12):1116-1125.

26. Younger J, Aron A, Parke S, Chatterjee N, Mackey S. Viewing pictures of a romantic partner reduces experimental pain: involvement of neural reward systems. PLoS One. 2010;5(10):e13309.

27. Borsook D, Becerra LR. Breaking down the barriers: fMRI applications in pain, analgesia, and analgesics. Mol Pain. 2006;2:30.

28. Koyama TM, Laurienti PJ, Coghill RC. The subjective experience of pain: where expectations become reality. Proc Natl Acad Sci USA. 2005;102(36):12950-12955.

29. Ohsner K, Ludlow D, Knierim K, et al. Neural correlates of individual differences in pain-related fear and anxiety. Pain. 2006;120:69-77.

30. Coghill RC, Sang CN, Maisog JM, Iadarola MJ. Pain intensity processing within the human brain: a bilateral, distributed mechanism. J Neurophysiol. 1999;82(4):1934-1943

31. Chiu IM, von Hehn CA, Woolf CJ. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat Neurosci. 2012;15(8):1063-1067.

32. Garland EL. Pain processing in the human nervous system: a selective review of nociceptive and biobehavioral pathways. Prim Care. 2012;39(3):561-571.

33. 33.Schaible HG, Ebersberger A, Natura G. Update on peripheral mechanisms of pain: beyond prostaglandins and cytokines. Arthritis Res Ther. 2011;13:210.

34. 34.Michaud K, Bombardier C, Emery P. Quality of life in patients with rheumatoid arthritis: does abatacept make a difference? Clin Exp Rheumatol. 2007;25:S3-S45.

35. 35.Helfand M, Freeman M. Assessment and Management of Acute Pain in Adult Medical Inpatients: A Systematic Review. Available at Last accessed October 21, 2022.

36. 36.Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.

37. 37.Kulkantrakorn K. Emerging concepts and treatment in neuropathic pain. Neurology Asia. 2012;17:265-271.

38. 38.Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807-819.

39. 39.Baron R. Mechanisms of disease: neuropathic pain—a clinical perspective. Nat Clin Pract Neurol. 2006;2:95-106.

40. 40.Haanpää M, Hietaharju A. Central neuropathic pain. In: Kopf A, Patel NB (eds). Guide to Pain Management in Low-Resource Settings. Seattle, WA: IASP Press; 2010: 207-212.

41. 41.Leone C, Biasiotta A, La Cesa S, et al. Pathophysiological mechanisms of neuropathic pain. Future Neurology. 2011;6(4):497-509.

42. 42.Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states: maybe it is all in their head. Best Pract Res Clin Rheumatol. 2011;25(2):141-154.

43. 43.Clauw DJ. Fibromyalgia: update on mechanisms and management. J Clin Rheumatol. 2007;13:102-109

44. 44.Kato K, Sullivan PF, Evengard B, Pedersen NL. A population-based twin study of functional somatic syndromes. Psychol Med. 2009;39:497-505.

45. 45.Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390.

46. 46.Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998;80:981-988.

47. 47.Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50(3):944-952.

48. 48.Buskila D. Genetics of chronic pain states. Best Pract Res Clin Rheumatol. 2007;21:535-547.

49. 49.Williams H. Making a difference in chronic pain management. Nurs Times. 2003;99:42-43.

50. 50.Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain. 2009;10:777-791.

51. 51.Raphael KG, Natelson BH, Janal MN, Nayak S. A community-based survey of fibromyalgia-like pain complaints following the World Trade Center terrorist attacks. Pain. 2002;100:131-139.

52. 52.Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997;4(3):134-153.

53. 53.DeSantana JM, Sluka KA. Central mechanisms in the maintenance of chronic widespread noninflammatory muscle pain. Curr Pain Headache Rep. 2008;12(5):338-343.

54. 54.Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13(2):211.

55. 55.Flor H. New developments in the understanding and management of persistent pain. Curr Opin Psychiatry. 2012;25(2):109-113.

56. 56.Fu Y, Han J, Ishola T, et al. PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior. Mol Pain. 2008;4:26.

57. 57.Pedersen LH, Scheel-Kruger J, Blackburn-Munro G. Amygdala GABA-A receptor involvement in mediating sensory-discriminative and affective-motivational pain responses in a rat model of peripheral nerve injury. Pain. 2007;127:17-26.

58. 58.Zusman M. Forebrain-mediated sensitization of central pain pathways: "nonspecific" pain and a new image for MT. Man Ther. 2002;7:80-88.

59. 59.Rygh LJ, Tjølsen A, Hole K, Svendsen F. Cellular memory in spinal nociceptive circuitry. Scand J Psychol. 2002;43(2):153-159

60. 60.Brosschot JF. Cognitive-emotional sensitization and somatic health complaints. Scand J Psychol. 2002;43(2):113-121.

61. 61.Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth. 2010;105(S1):i69-i85.

62. 62.Staud R. Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions. Expert Rev Neurother. 2012;12(5):577-585.

63. 63.Tam E, Furlan AD. Transdermal lidocaine and ketamine for neuropathic pain: a study of effectiveness and tolerability. Open Neurol J. 2012;6:58-64.

64. 64.Staud R. Peripheral pain mechanisms in chronic widespread pain. Best Pract Res Clin Rheumatol. 2011;25(2):155-164.

65. 65.Schwartzman RJ, Alexander GM, Grothusen JR. The use of ketamine in complex regional pain syndrome: possible mechanisms. Expert Rev Neurother. 2011;11(5):719-734.

66. 66.Smith HS, Kara DK, Argoff CE. Management of neuropathic pain: current insights and future perspectives. US Neurology. 2012;8(1):57-61.

67. 67.Raffa RB, Pergolizzi JV Jr, Tallarida RJ. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain. 2010;11(8):701-709.

68. 68.European Urological Association. Guidelines on Pain Management and Palliative Care. Available at Last accessed October 21, 2022.

69. 69.Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S5.

70. 70.Whittle SL, Colebatch AN, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology. 2012;51:1416-1425.

71. 71.Xu B, Descalzi G, Ye HR, Zhuo M, Wang YW. Translational investigation and treatment of neuropathic pain. Mol Pain. 2012;8:15.

72. 72.Barkin RL, Barkin SJ, Barkin DS. Pharmacotherapeutic management of pain with a focus directed at the geriatric patient. Rheum Dis Clin North Am. 2007;33(1):1-31.

73. 73.Rahman W, D'Mello R, Dickenson AH. Peripheral nerve injury-induced changes in spinal alpha(2)-adrenoceptor-mediated modulation of mechanically evoked dorsal horn neuronal responses. J Pain. 2008;9:350-359.

74. 74.Marks DM, Shah MJ, Patkar AA, et al. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise.Cur Neuropharmacology. 2009;7(4):331-336.

75. 75.Blonk MI, Koder BG, van den Bemt P, Huygen FJ. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2009;14(5):466-472.

76. 76.Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis. Pain Med. 2012;13(2):263-269.

77. 77.Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo-controlled study. Pain. 2009;147(1-3):107-115.

78. 78.Dinakar P. Pain management. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ (eds). Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Saunders; 2021.

79. 79.Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013;16(1):27-40.

80. 80.Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29(2):162-171.

81. 81.Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857-864.

82. 82.Costigan M, Latremoliere A, Woolf CJ. Analgesia by inhibiting tetrahydrobiopterin synthesis. Curr Opin Pharmacol. 2012;12(1): 92-99.

83. 83.McCleane GJ, Suzuki R, Dickenson AH. Does a single intravenous injection of the 5HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study. Anesth Analg. 2003;97(5):1474-1478.

84. 84.Stevans JM, Saper RB. Chronic low back pain. In: Rakel D, Minichiello V (eds). Integrative Medicine. 5th ed. Philadelphia, PA: Saunders; 2022.

85. 85.Balagué F, Mannion AF, Pellisé F, Cedraschi C. Nonspecific low back pain. Lancet. 2012;379(9814):482-491.

86. 86.McCarberg B, Peppin J. Pain pathways and nervous system plasticity: learning and memory in pain. Pain Med. 2019;20(12):2421-2437.

87. 87.Nijs J, Leysen L, Vanlauwe, J, et al. Treatment of central sensitization in patients with chronic pain: time for change? Expert Opin Pharmacother. 2019;20(16):1961-1970.

88. 88.Ji RR, Nackley A, Huh Y, et al. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018;129(2):343-366.

Copyright © 2022 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.